Shares of Cipla emerged as the top gainer on the Nifty index after the pharmaceutical major reported its March quarter earnings, with investors and brokerage firms choosing to look beyond the sharp decline in bottom-line performance. The stock rose more than 8 percent during Thursday’s trading session and extended gains for a second consecutive day, taking its two-session rise beyond 11 percent.

The rally came despite Cipla reporting a 55 percent year-on-year decline in consolidated net profit for the March quarter at Rs 542.51 crore. Ordinarily, such a steep fall in profitability would trigger caution among investors. However, market participants appeared to interpret the earnings in a broader strategic context rather than reacting solely to headline profit numbers.

Brokerage commentary following the results remained largely constructive, with analysts highlighting the company’s resilient India business, improving product mix, and continued traction in regulated international markets. The management’s commentary around future growth visibility and pipeline execution also appears to have reassured investors that the quarter’s earnings pressure may not necessarily reflect a structural slowdown.

The market reaction underscores an important trend currently visible in Indian pharmaceutical stocks. Investors are increasingly rewarding companies that demonstrate long-term earnings visibility, stable domestic demand, and strong execution capabilities, even when near-term profitability fluctuates because of one-off factors, pricing adjustments, or base effects.

Cipla’s India formulation business continues to remain a central pillar for the company. Domestic pharmaceutical demand in India has remained relatively resilient compared to several global markets, aided by chronic therapy growth, higher healthcare awareness, and steady prescription expansion. Companies with strong respiratory, cardiac, and anti-infective portfolios have particularly benefited from stable demand trends.

Another factor supporting investor confidence is Cipla’s exposure to the United States market. While pricing pressure in the US generics business remains an industry-wide challenge, brokerages reportedly remain optimistic about the company’s future launches and specialty product opportunities. A steady pipeline in regulated markets often plays a crucial role in determining valuation multiples for large Indian pharmaceutical exporters.